Identification of NK Cell Subpopulations That Differentiate HIV-Infected Subject Cohorts with Diverse Levels of Virus Control.


Journal

Journal of virology
ISSN: 1098-5514
Titre abrégé: J Virol
Pays: United States
ID NLM: 0113724

Informations de publication

Date de publication:
01 04 2019
Historique:
received: 09 10 2018
accepted: 19 01 2019
pubmed: 1 2 2019
medline: 19 11 2019
entrez: 1 2 2019
Statut: epublish

Résumé

HIV infection is controlled immunologically in a small subset of infected individuals without antiretroviral therapy (ART), though the mechanism of control is unclear. CD8

Identifiants

pubmed: 30700608
pii: JVI.01790-18
doi: 10.1128/JVI.01790-18
pmc: PMC6430550
pii:
doi:

Substances chimiques

CD11b Antigen 0
CD56 Antigen 0
CD57 Antigens 0
DNA, Viral 0
NK Cell Lectin-Like Receptor Subfamily B 0
Receptors, IgG 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIAID NIH HHS
ID : P30 AI027763
Pays : United States

Informations de copyright

Copyright © 2019 American Society for Microbiology.

Références

J Immunol. 2005 Dec 15;175(12):7791-5
pubmed: 16339512
Retrovirology. 2013 Dec 18;10:158
pubmed: 24351015
J Exp Med. 1996 Nov 1;184(5):1845-56
pubmed: 8920872
Immunity. 2007 Sep;27(3):406-16
pubmed: 17892849
Immunol Cell Biol. 2014 Mar;92(3):221-9
pubmed: 24366519
AIDS. 2017 Nov 13;31(17):2317-2330
pubmed: 28926399
PLoS Pathog. 2015 Nov 05;11(11):e1005233
pubmed: 26539983
Annu Rev Immunol. 1998;16:359-93
pubmed: 9597134
Nat Med. 1996 Mar;2(3):338-42
pubmed: 8612235
J Immunol. 2005 Dec 15;175(12):7796-9
pubmed: 16339513
Science. 2018 Jan 5;359(6371):86-90
pubmed: 29302013
AIDS. 2015 Sep 10;29(14):1767-73
pubmed: 26372382
Nat Genet. 2002 Aug;31(4):429-34
pubmed: 12134147
AIDS. 2005 Nov 18;19(17):2001-7
pubmed: 16260907
AIDS Res Hum Retroviruses. 2017 Dec;33(12):1205-1213
pubmed: 28810810
Cell Rep. 2018 Feb 13;22(7):1875-1888
pubmed: 29444438
Scand J Immunol. 2016 Sep;84(3):182-90
pubmed: 27312286
J Infect Dis. 1991 May;163(5):959-65
pubmed: 1673465
Sci Transl Med. 2014 Sep 24;6(255):255ra131
pubmed: 25253674
Proc Natl Acad Sci U S A. 2014 Jan 7;111(1):202-7
pubmed: 24344260
Trends Immunol. 2010 Nov;31(11):401-6
pubmed: 20829113
Clin Immunol. 2008 Jul;128(1):46-56
pubmed: 18495540
J Virol. 2009 May;83(10):5028-34
pubmed: 19211742
J Acquir Immune Defic Syndr. 2010 Apr;53(5):564-73
pubmed: 20147841
Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2709-14
pubmed: 10694578
J Virol. 2017 Nov 14;91(23):
pubmed: 28956765
Immunol Rev. 2006 Dec;214:47-55
pubmed: 17100875
Blood. 2009 Apr 23;113(17):3978-89
pubmed: 19109229
Cell Rep. 2015 Apr 7;11(1):85-97
pubmed: 25818301
J Immunol. 2009 Nov 15;183(10):6612-8
pubmed: 19846870
Science. 2010 Dec 10;330(6010):1551-7
pubmed: 21051598
Cytometry A. 2012 Jun;81(6):467-75
pubmed: 22577098
J Clin Microbiol. 2016 Apr;54(4):902-11
pubmed: 26763968
J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Nov 1;10(3):331-40
pubmed: 7552495
J Gen Virol. 2007 Jan;88(Pt 1):242-50
pubmed: 17170457
Nat Protoc. 2015 Feb;10(2):316-33
pubmed: 25612231
Nat Med. 2003 Jun;9(6):727-8
pubmed: 12754504
Cytometry A. 2014 Dec;85(12):1011-9
pubmed: 25274027
Clin Infect Dis. 2005 Oct 1;41(7):1053-6
pubmed: 16142675
Blood. 2009 Oct 29;114(18):3822-30
pubmed: 19710502
Trends Immunol. 2001 Nov;22(11):633-40
pubmed: 11698225
AIDS. 2008 Jul 31;22(12):1487-91
pubmed: 18614872
Gut. 2016 Dec;65(12):1998-2006
pubmed: 26674359
J Exp Med. 2007 Nov 26;204(12):3027-36
pubmed: 18025129
Cytometry A. 2013 May;83(5):483-94
pubmed: 23512433
Science. 2011 May 6;332(6030):687-96
pubmed: 21551058
Nat Immunol. 2002 Nov;3(11):1061-8
pubmed: 12368910
Proc Natl Acad Sci U S A. 2013 Jul 16;110(29):11970-5
pubmed: 23818644
Front Immunol. 2018 Apr 09;9:486
pubmed: 29686665
EBioMedicine. 2017 Feb;16:141-149
pubmed: 28159573
Nat Protoc. 2008;3(7):1240-8
pubmed: 18600229
Blood. 2005 Nov 15;106(10):3366-9
pubmed: 16002429
Blood. 2010 Nov 11;116(19):3865-74
pubmed: 20733159
J Virol. 2010 Jan;84(2):1183-8
pubmed: 19906929
Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15011-6
pubmed: 14645713
J Exp Med. 2007 Oct 1;204(10):2473-85
pubmed: 17893201
Proc Natl Acad Sci U S A. 2007 Apr 17;104(16):6776-81
pubmed: 17428922
Blood. 2006 Jun 15;107(12):4781-9
pubmed: 16467198
Front Immunol. 2013 Dec 09;4:422
pubmed: 24367364
J Acquir Immune Defic Syndr. 2013 Aug 1;63(4):438-41
pubmed: 23493152
J Infect Dis. 2015 Nov 1;212(9):1361-5
pubmed: 25877550
PLoS Pathog. 2013 Feb;9(2):e1003174
pubmed: 23459007
J Virol. 2012 Dec;86(24):13679-88
pubmed: 23055552
AIDS. 2008 Mar 12;22(5):595-9
pubmed: 18317000
Proc Natl Acad Sci U S A. 2014 Jul 1;111(26):E2770-7
pubmed: 24979804
Eur J Immunol. 2003 Sep;33(9):2410-8
pubmed: 12938217
J Exp Med. 1995 Oct 1;182(4):1045-56
pubmed: 7561678
Immunology. 2008 Feb;123(2):164-70
pubmed: 17627773
J Virol. 2008 Jun;82(11):5398-407
pubmed: 18353945
Curr Opin HIV AIDS. 2013 May;8(3):170-5
pubmed: 23564004
Nature. 2011 Aug 03;476(7358):96-100
pubmed: 21814282
Nat Genet. 2007 Jun;39(6):733-40
pubmed: 17496894
Immunology. 2014 Apr;141(4):483-9
pubmed: 24303897
Immunology. 2011 Jul;133(3):350-9
pubmed: 21506999

Auteurs

Christopher W Pohlmeyer (CW)

Gilead Sciences, Inc., Foster City, California, USA.

Veronica D Gonzalez (VD)

Department of Microbiology and Immunology, Baxter Laboratory in Stem Cell Biology, Stanford University, Stanford, California, USA.

Alivelu Irrinki (A)

Gilead Sciences, Inc., Foster City, California, USA.

Ricardo N Ramirez (RN)

Gilead Sciences, Inc., Foster City, California, USA.

Li Li (L)

Gilead Sciences, Inc., Foster City, California, USA.

Andrew Mulato (A)

Gilead Sciences, Inc., Foster City, California, USA.

Jeffrey P Murry (JP)

Gilead Sciences, Inc., Foster City, California, USA.

Aaron Arvey (A)

Gilead Sciences, Inc., Foster City, California, USA.

Rebecca Hoh (R)

Division of HIV, Infectious Diseases and Global Medicine, University of California, San Francisco, San Francisco, California, USA.

Steven G Deeks (SG)

Division of HIV, Infectious Diseases and Global Medicine, University of California, San Francisco, San Francisco, California, USA.

George Kukolj (G)

Gilead Sciences, Inc., Foster City, California, USA.

Tomas Cihlar (T)

Gilead Sciences, Inc., Foster City, California, USA.

Stefan Pflanz (S)

Gilead Sciences, Inc., Foster City, California, USA.

Garry P Nolan (GP)

Department of Microbiology and Immunology, Baxter Laboratory in Stem Cell Biology, Stanford University, Stanford, California, USA.

Gundula Min-Oo (G)

Gilead Sciences, Inc., Foster City, California, USA gundula.min-oo@gilead.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH